Pharmaceutical Industry, International Community Must Place Drug-Resistant TB On Agenda

Writing in The Guardian’s “Global Development Professionals Network” blog, Emily Wise, a doctor volunteering with Médecins Sans Frontières/Doctors Without Borders (MSF) in Karakalpakstan, Uzbekistan, an area where drug-resistant tuberculosis (TB) is endemic, examines the conflict surrounding the treatment of the disease with a drug that can cause depression and suicidal thoughts. “It’s not underlying mental illness that causes people on TB drugs to become depressed. It’s a chemical effect resulting from the ingestion of cycloserine, one of the cocktail of drugs we must use to treat drug-resistant TB,” she writes, noting, “Though cycloserine is primarily to blame, there can be no denying that other things contribute to episodes,” such as “[t]he stigma of being a TB patient, a patient’s pill burden (the number of drugs they have to take on a daily basis) and the duration of the treatment.” She continues, “I’m forced to acknowledge that the tools we currently have against drug-resistant TB are, at best, just a holding measure and not a solution,” concluding, “We need the pharmaceutical industry and the international community to put this disease on their agenda and give doctors and patients what they so desperately need: new compounds against drug-resistant TB” (8/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.